Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-Deoxyuridine 5'-alpha,beta-imido-triphosphate is a synthetic, non-hydrolyzable analog of deoxyuridine triphosphate (dUTP). It is primarily used as a biochemical tool and research reagent to study the function and structural dynamics of deoxyuridine triphosphate nucleotidohydrolase (dUTPase), an enzyme essential for nucleotide metabolism. This compound mimics the natural substrate but resists enzymatic hydrolysis due to its imido linkage between the alpha and beta phosphate groups. By binding tightly to dUTPase without being cleaved, it allows researchers to trap specific conformational states of the enzyme for kinetic, structural, or mechanistic studies. The main mechanism involves competitive inhibition at the active site of dUTPases from various organisms including humans, Mycobacterium tuberculosis, and Escherichia coli[1][4][7][9]. There are no known therapeutic indications; its use is restricted to laboratory research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-deoxyuridine 5'-alpha,beta-imido-triphosphate.